Illuminare Biotechnologies reported first‑in‑human Phase 1 results for Illuminare‑1, an imaging agent that fluoresces under blue light by binding myelin, showing rapid onset and sustained nerve visualization. The company highlighted the agent’s potential to reduce iatrogenic nerve injury across diverse surgeries. Chief medical officer Stewart McCallum contextualized the trial as an initial safety and feasibility readout; broader clinical evaluation will be needed to assess impact on surgical outcomes and rates of long‑term nerve damage.